Valneva (NASDAQ:VALN) Sets New 52-Week Low – Here’s Why

Valneva SE Sponsored ADR (NASDAQ:VALN) shares reached a new 52-week low on Monday . The stock traded as low as $5.04 and last traded at $5.3330, with a volume of 27494 shares traded. The stock had previously closed at $5.19.

Analyst Upgrades and Downgrades

VALN has been the topic of several analyst reports. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Guggenheim set a $11.00 price objective on shares of Valneva in a research note on Thursday, April 16th. The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Valneva currently has a consensus rating of “Hold” and a consensus target price of $11.97.

Valneva Stock Up 0.0%

The firm has a 50-day moving average price of $5.63 and a two-hundred day moving average price of $7.87. The company has a market capitalization of $492.57 million, a P/E ratio of -2.78 and a beta of 1.75. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The company had revenue of $35.77 million for the quarter. Equities research analysts anticipate that Valneva SE Sponsored ADR will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Valneva during the fourth quarter worth about $44,000. Marex Group plc acquired a new position in Valneva in the 2nd quarter valued at approximately $64,000. XTX Topco Ltd bought a new stake in shares of Valneva in the 4th quarter worth approximately $94,000. VSM Wealth Advisory LLC lifted its position in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Valneva during the 3rd quarter worth approximately $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.